XML 50 R40.htm IDEA: XBRL DOCUMENT v3.25.3
Earnings Per Common Share And Share Awards Summary Of Share-Based Award Transactions (Details) - SARs - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award, SARS, Outstanding [Roll Forward]          
Number of shares, outstanding beginning balance     28 42  
Number of shares, SARs granted 5 5 5 5  
Number of shares, SARS exercised     (7) (19)  
Number of shares, SARS forfeited or expired     (2)    
Number of shares, outstanding ending balance 24   24 28 42
Number of shares, exercisable as of September 30, 2025 20   20    
Number of shares, unvested as of September 30, 2025 4   4    
Share-based Compensation Arrangement by Share-based Payment Award, SARs, Outstanding, Weighted Average Exercise Price [Roll Forward]          
Weighted average exercise price, outstanding beginning balance     $ 154.71 $ 160.83  
Weighted average exercise price, SARs granted     246.75 160.94  
Weighted average exercise price, SARS exercised     160.62 170.21  
Weighted average exercise price, forfeited or expired     146.00    
Weighted average exercise price, outstanding ending balance $ 170.67   170.67 $ 154.71 $ 160.83
Weighted average exercise price, exercisable as of September 30, 2025 164.98   164.98    
Weighted average exercise price, unvested as of September 30, 2025 $ 195.21   $ 195.21    
Average remaining contractual term, outstanding beginning balance     4 years 1 month 28 days 3 years 10 months 24 days 3 years 8 months 8 days
Average remaining contractual term, outstanding ending balance     4 years 1 month 28 days 3 years 10 months 24 days 3 years 8 months 8 days
Average remaining contractual term, exercisable as of September 30, 2025     3 years 11 months 4 days    
Average remaining contractual term, unvested as of September 30, 2025     5 years 1 month 28 days    
Aggregate intrinsic value, outstanding beginning balance     $ 2,312 $ 428  
Aggregate intrinsic value, outstanding ending balance $ 2,349   2,349 $ 2,312 $ 428
Aggregate intrinsic value, exercisable as of September 30, 2025 2,018   2,018    
Aggregate intrinsic value, unvested as of September 30, 2025 $ 331   $ 331